Benitec Biopharma (NASDAQ:BNTC) Given "Buy" Rating at HC Wainwright

Benitec Biopharma (NASDAQ:BNTC - Get Free Report)'s stock had its "buy" rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Monday,Benzinga reports. They currently have a $28.00 price objective on the biotechnology company's stock. HC Wainwright's target price points to a potential upside of 108.49% from the company's current price.

A number of other equities analysts have also recently issued reports on BNTC. Robert W. Baird initiated coverage on Benitec Biopharma in a report on Friday, December 13th. They set an "outperform" rating and a $30.00 target price on the stock. Baird R W upgraded shares of Benitec Biopharma to a "strong-buy" rating in a report on Thursday, December 12th. Finally, Guggenheim reaffirmed a "buy" rating and issued a $17.00 target price on shares of Benitec Biopharma in a research note on Tuesday, December 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $24.43.

Benitec Biopharma Stock Down 2.2 %

NASDAQ BNTC traded down $0.30 during trading hours on Monday, hitting $13.43. The company's stock had a trading volume of 54,182 shares, compared to its average volume of 54,904. Benitec Biopharma has a twelve month low of $4.75 and a twelve month high of $16.90. The firm has a market capitalization of $314.95 million, a P/E ratio of -8.89 and a beta of 0.92. The stock has a fifty day moving average of $12.25 and a 200 day moving average of $11.12.

Remove Ads

Benitec Biopharma (NASDAQ:BNTC - Get Free Report) last issued its earnings results on Friday, February 14th. The biotechnology company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.55) by $0.19. On average, analysts predict that Benitec Biopharma will post -1.48 earnings per share for the current year.

Insider Buying and Selling

In other Benitec Biopharma news, Director Suvretta Capital Management, L acquired 900,000 shares of Benitec Biopharma stock in a transaction dated Wednesday, March 26th. The stock was bought at an average cost of $13.00 per share, for a total transaction of $11,700,000.00. Following the purchase, the director now directly owns 8,793,245 shares in the company, valued at approximately $114,312,185. This represents a 11.40 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.30% of the company's stock.

Institutional Trading of Benitec Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of BNTC. Acuta Capital Partners LLC bought a new position in Benitec Biopharma in the third quarter valued at approximately $274,000. Ameriprise Financial Inc. boosted its holdings in shares of Benitec Biopharma by 138.4% in the 4th quarter. Ameriprise Financial Inc. now owns 35,476 shares of the biotechnology company's stock valued at $448,000 after buying an additional 20,597 shares during the last quarter. 683 Capital Management LLC bought a new position in shares of Benitec Biopharma in the fourth quarter valued at $452,000. Northern Trust Corp increased its holdings in Benitec Biopharma by 54.2% during the fourth quarter. Northern Trust Corp now owns 38,200 shares of the biotechnology company's stock worth $482,000 after buying an additional 13,425 shares during the last quarter. Finally, MYDA Advisors LLC bought a new stake in Benitec Biopharma during the fourth quarter worth $632,000. Institutional investors own 52.19% of the company's stock.

Benitec Biopharma Company Profile

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.